Tema Etfs LLC Invests $253,000 in AnaptysBio, Inc. $ANAB

Tema Etfs LLC purchased a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) during the 2nd quarter, HoldingsChannel reports. The fund purchased 11,404 shares of the biotechnology company’s stock, valued at approximately $253,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Invesco Ltd. grew its holdings in AnaptysBio by 289.8% during the second quarter. Invesco Ltd. now owns 83,174 shares of the biotechnology company’s stock worth $1,846,000 after acquiring an additional 61,838 shares during the period. Arrowstreet Capital Limited Partnership bought a new position in shares of AnaptysBio during the 2nd quarter valued at about $3,348,000. Panagora Asset Management Inc. acquired a new position in shares of AnaptysBio in the 2nd quarter worth approximately $741,000. Russell Investments Group Ltd. bought a new stake in shares of AnaptysBio in the 2nd quarter worth approximately $528,000. Finally, XTX Topco Ltd acquired a new stake in AnaptysBio during the second quarter valued at approximately $680,000.

AnaptysBio Trading Up 2.4%

Shares of NASDAQ:ANAB opened at $44.35 on Friday. The stock has a market capitalization of $1.23 billion, a PE ratio of -15.73 and a beta of 0.29. AnaptysBio, Inc. has a 1 year low of $12.21 and a 1 year high of $45.32. The firm has a fifty day moving average price of $35.72 and a 200 day moving average price of $27.22.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, topping the consensus estimate of ($1.06) by $1.58. The firm had revenue of $76.32 million during the quarter, compared to analyst estimates of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. On average, sell-side analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio declared that its Board of Directors has initiated a stock repurchase plan on Friday, November 21st that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the biotechnology company to repurchase up to 9.6% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

ANAB has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, October 8th. Wells Fargo & Company upped their target price on AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Guggenheim increased their price target on AnaptysBio from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Barclays cut their price objective on AnaptysBio from $83.00 to $70.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Finally, HC Wainwright decreased their target price on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating for the company in a report on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $59.30.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.